Datasets:
ESGBERT
/
base_data

Dataset card Data Studio Files
xet
 Community
sentence
stringlengths
1
23.5k
⌀
We felt this would appeal to the variety of our stakeholders, facilitating data transparency and enabling us to share the stories that bring our program to life for reviewers.
We heard from our investor community that we could go into greater detail about the potential financial impacts of sustainability on our business and how we assessed opportunities and risk associated with climate change.
A. We have expanded our reporting framework to include GRI plus the recommendations from the Sustainability Accounting Standards Board (SASB) and the Task Force on Climate-related Financial Disclosures (TCFD).
We believe this approach will enable us to further provide an integrated, comprehensive view of our activities and our progress on commitments related to sustainability, climate action, and social responsibility.
We recognize that stewardship of our fiduciary responsibility includes a strong emphasis on managing risk, driving performance, and ensuring business integrity.
CSR provides a lens through which to evaluate business opportunities and to ensure decisions benefit all our stakeholders—not just investors, but also employees, customers, suppliers, the environment, and the communities in which we operate.
There is much to be optimistic about in the global recovery path and the role of genomics in general.
While some labs are still not operating at their pre-pandemic levels, we see very positive signs that our business is trending in the right direction.
We saw a faster recovery than expected, in both clinical and research customers, leading to a strong rebound in our business by the second half of the year.
Despite the many challenges of we still had several ground-breaking activities.
We launched NextSeqTM and NextSeqTM 1000, as well as the P3 flow cells.
In addition, we rolled out the NovaSeqTM COVIDSeqTM, the first NGS-based test to receive Emergency Use Authorization (EUA) from the FDA.
Our research and development (R&D) investments grew both sequentially and year-over-year.
We contributed to some remarkable scientific and medical genomic breakthroughs this year, and witnessed continued adoption of NGS in cancer treatment.
We also saw expanded coverage and access to NIPT for all pregnant women, regardless of risk.
Finally, there is a greater appreciation of the need for genomic surveillance of COVID-the emergence of new strains and raised awareness of the critical role sequencing can play with infectious disease.
I am confident that our portfolio is stronger than ever.
We are an applied genomics technology company and the global leader in DNA sequencing and array-based technologies.
At the intersection of biology and technology, genomics is having a transformative effect across everything from healthcare and sustainable agriculture to data storage.
Our first products enabled researchers to explore DNA on an entirely new scale.
This helped to create the first map of gene variations associated with health, disease, and drug response.
This set the groundwork for many other discoveries in the future.
We are striving to continue opening up unprecedented access to the incredible potential of genomics.
During the first chapter of genomics, we pioneered technology that has the capacity to see into the genome.
Since then, we have endeavored to make the genome more accessible to ensure that the extraordinary potential of these scientific breakthroughs has a truly global reach.
Illumina is ready to embark on the next chapter of genomic applications.
This will involve further empowering our partners and helping them to predict and prevent a wider range of diseases, making personalized medicine a reality.
With progress in this field, we believe genomic advances should be applied responsibly, diligently, and, above all, ethically.
Today’s discoveries offer new treatments and fresh hope to the patients of tomorrow.
We are working tirelessly to create the leading-edge technology required to enable clinicians and researchers to not only understand the genome, but also fully tap into its power.
Service & Other We provide warranties and maintenance contracts for our systems, and undertake services at our in-house labs.
Our range of sequencing systems spans the full range of applications.
In addition, we offer a microarray instrument to support genotyping.
The complete Board of Directors provides guidance and direction on environmental, social, and governance issues and opportunities that have potential impact on reputation and long-term economic viability, including climate action.
Illumina’s Executive CSR Steering Committee, chaired by the Chief Financial Officer (CFO), is comprised of a team of senior leaders drawn from across the organization that provide guidance on strategic plans, and review progress on a quarterly basis.
The CSR programs are embedded into our business through several supporting working groups, including the Diversity & Inclusion Council; Environment, Health & Safety Steering Committee; Quality Council; Public Policy Committee; Illumina Cares Champions; Sustainability Green Teams; and employee resource groups (ERGs).
Giving governance for Illumina, Inc. is led by the Corporate Citizenship Steering Committee.
to Genomics We strive to remove barriers of access and increase representation of global diversity to expand the transformative benefits of genomics for all.
Our Strategy: Creating Unique Impact Our CSR strategy focuses on our most significant and material issues, our stakeholders, and the areas where we can uniquely impact the global community.
We are dedicated to positively impacting humanity through both our technology and actions.
to Genomics, Empowering Our Communities, and Environmental Sustainability.
goals we can most uniquely impact: Our People We cultivate an agile, innovative workplace, and a culture fueled by collaboration, diversity, inclusion, and fairness.
We align our business principles with our core values, ethical responsibilities, and legal obligations.
Empower Our Communities We share our time, talent, and technology with the communities where we live and work.
Environmental Sustainability We invest in sustainable solutions across our facilities, supply chain, and products.
We believe that pursuing our mission to improve human health extends beyond bringing innovative technologies to market.
and Security Note: In this report, we use the terms “material” and “materiality” to refer to topics that reflect Illumina’s meaningful environmental, social, and governance impact.
To inform our CSR strategy, we engaged with a wide range of stakeholders.
Our internal engagement encompassed all organizational levels, while our external engagement included representatives from global, national, and local interests.
We are relentless in our pursuit to improve human health.
We recognize that a key component of our work is making genomic technology more accessible to people and places around the world.
Through our programs and partnerships, we aim to remove barriers of access and increase equity of representation to expand the benefits of genomics for all.
A: NGS has played a critical role in everything from identification of the virus to understanding transmission routes, viral mutation rates, and genome evolution, and has served as a foundation for vaccine development and therapies.
NGS is a critical part of predicting and preventing future outbreaks.
One of the primary advantages NGS provides over other methods of analysis is that it is an effective and high-throughput solution for screening multiple samples and detecting viruses and other pathogens without prior knowledge of an infectious agent.
Once an organism is identified, NGS workflows can be used to detect a pathogen, perform surveillance and epidemiological studies, track mutational changes in the pathogen’s genome, enable unbiased discovery of co-infections, and analyze potential susceptibility and human response to infection.
Five main ways sequencing-based surveillance has been used to fight SARS-CoV- 1.
Identified the virus causing the respiratory illnesses in Wuhan, China 2.
Determines how quickly the virus is adapting as it spreads 4.
Identifies host genetics associated with severe disease 5.
of effective therapies and vaccine NGS has played a critical role in everything from identification of the virus to understanding transmission routes, viral mutation rates, and genome evolution, and has served as a foundation for vaccine development and therapies.
A: NGS is contributing significantly to the global response to SARS-CoV-the world to prepare for future pandemics.
The COVID-need for tools to detect and monitor emerging pathogens like SARS-CoV-2.
We saw the use of sequencing to resolve epidemiological uncertainties by linking ambiguous cases with established transmission pathways and separate local transmission events from those that were imported from a different region.
In addition, we simply would not have effective and authorized vaccines without the widespread use of NGS.
We know the routine use of genomics will be a required part of global surveillance systems to spot potential threats earlier and faster.
These systems require local capabilities to collect and analyze samples as well as mechanisms to aggregate pathogen genomes across national boundaries to rapidly identify emerging threats.
This pandemic has highlighted the increased threat of infectious disease in a world that is so interconnected.
Genomics can help us respond faster and more efficiently, and leverage the strength of working together.
A: On several levels, highlighted the inequities of vulnerable populations, underrepresented groups and geographies.
There are still tremendous gaps in access to genomic technology, personalized medicine, and even representative data to understand genomes in the context of global diversity.
While we are working to increase access to genomics through innovation, education for healthcare professionals, and collaborations to improve market access, we are also focused on removing barriers through our philanthropic contributions.
COVID-vulnerable population of children and their families seeking help for undiagnosed and rare disease.
We continued to support patients through iHope this year, and added a clinic in Africa to the network.
We are hopeful that as we recover from the pandemic, we can continue to grow the number of patients we can impact with this program.
Polyethnic-the GINGER fellowship at the Broad Institute, and the launch of the Africa Pathogen Genomics Initiative (APGI).
We will continue to seek opportunities to champion patients and access.
we understand that today’s discoveries have the potential to help tomorrow’s patients.
We recognize that our efforts to improve human health can be magnified if all people and places have access to genomic technology.
Having been integrated into clinical practice at a faster rate than almost any innovation in the history of medicine, it is today creating a path toward personalized medicine and inspiring hope worldwide.
This implementation has, however, been almost entirely restricted to more developed nations.
There is a vital need to make genomic technology and precision medicine available to all, regardless of their social status, income, or geographic location.
Cutting-edge technologies help patients to be diagnosed quicker and more accurately.
While we are driving down the cost of sequencing with innovation and advocating for increased coverage and reimbursement through education, obstacles still exist in terms of varying adoption rates around the globe.
Through innovation, philanthropy, education, and collaboration, we will break down barriers and continue to seek new ways to drive progress in the adoption of genomics for all.
Enabling Innovation Thirty years ago, the Human Genome Project sparked a revolution in technology and genomic understanding that continues to advance at great speed.
The genomics revolution has enabled the use of Non-Invasive Prenatal Testing (NIPT) and helped thousands of patients with rare disease receive a diagnosis in weeks rather than years.
Research is continuing to help us learn more about human health, to better understand the population and biomes in which we live, and to provide insights that improve our understanding about how we can utilize the world’s natural resources in a more sustainable way.
Thousands of scientists worked for decades to sequence the first genome.
Today, thanks to the power, efficiency, and throughput of our NovaSeqTM sequencing systems, the same feat can be accomplished in a day, and at a fraction of the original cost.
The Human Genome Project was a unique opportunity to interrogate life’s software: DNA.
It was a legacy project that will continue to light the way for generations to come.
Chief Product Officer Enabling Innovation In completed a composite sequence of the full human genome at a cost of almost $3 billion.
Since then, the cost to decode a genome has been decreasing fast—from hundreds of thousands of dollars per person to approximately $1,000 in 2014.
In we launched the NovaSeqTM and made significant progress toward realizing the $100 genome.
This year, another significant step forward was achieved with the release of the NovaSeqTM Kit, which further reduced the cost to $600 per genome.
We are proud that Illumina’s technology is helping scientists to make major discoveries by enabling whole genome sequencing to be accessible and affordable for labs of all sizes.
Our pioneering technology and leading-edge advancements have allowed researchers to uncover the genome’s potential, enabling life-impacting science on everything from COVID-and sustainable agriculture.
We will continue to innovate and develop technology that provides unprecedented access to the genome, with more data processing power, more efficiency, and greater affordability.
iHope is a philanthropic consortium that provides whole genome sequencing to underserved families around the globe.